Predictors and Long-Term Outcomes for Diffuse Large B-Cell Lymphoma (DLBCL) Patients Undergoing Surgery Prior to Systemic Therapy: A Nationwide Analysis

A minority of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) undergo surgery before the initiation of systemic therapy. The aim of this study is to explore the characteristics of patients undergoing surgery prior to systemic therapy (surgfirst), the predictors for surgfirst, and the s...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2022-04, Vol.14 (4), p.e24448
Main Authors: Vusqa, Urwat, Jayakrishnan, Thejus T, Bakalov, Veli, Chahine, Zena, Wegner, Rodney, Khan, Cyrus, Fazal, Salman, Samhouri, Yazan, Malayala, Srikrishna V, Lister, John
Format: Article
Language:English
Subjects:
Accreditation
Cancer therapies
Chemotherapy
Comorbidity
Hematology
Hispanic Americans
Lymphoma
Male reproductive system
Medicare
Oncology
Patients
Sociodemographics
Socioeconomic factors
Surgery
Survival analysis
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A minority of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) undergo surgery before the initiation of systemic therapy. The aim of this study is to explore the characteristics of patients undergoing surgery prior to systemic therapy (surgfirst), the predictors for surgfirst, and the survival outcomes. The National Cancer Database was queried for patients with DLBCL diagnosed between 2006 and 2015, and we performed a subgroup analysis of patients that received surgfirst. Time-to-initial therapy (TTI) was defined as the time in days (d) from diagnosis to systemic therapy. Overall survival was measured from the day of diagnosis in terms of months (m). Factors associated with lower likelihood of surgfirst were non-Hispanic Black race (p-value
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.24448